Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Carcinoembryonic antigen DNA vaccine (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms El-porCEA
- 10 Jun 2017 Biomarkers information updated
- 24 Mar 2012 Last checked against European Clinical Trials Database record.
- 27 Feb 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.